| Literature DB >> 27581760 |
Regina Kuhmmer1,2, Rosmeri Kuhmmer Lazzaretti3,4, Cátia Moreira Guterres3, Fabiana Viegas Raimundo3,5, Leni Everson Araújo Leite3, Tássia Scholante Delabary3, Suhelen Caon3, Gisele Alsina Nader Bastos3,5, Carisi Anne Polanczyk3,4.
Abstract
BACKGROUND: Hypertension is a public health problem and a major risk factor for cardiovascular disease. The purpose of this study is to compare the effectiveness of a multidisciplinary program based on group and individual care versus group-only care, to promote blood pressure control in hypertensive patients in primary health care.Entities:
Keywords: Diabetes Mellitus; Diastolic blood pressure; Hypertension; Multidisciplinary program; Public health; Systolic blood pressure
Mesh:
Year: 2016 PMID: 27581760 PMCID: PMC5006538 DOI: 10.1186/s12913-016-1703-0
Source DB: PubMed Journal: BMC Health Serv Res ISSN: 1472-6963 Impact factor: 2.655
Fig. 1Study flow diagram
Sociodemographic, clinical and behavioral characteristics of participants
| Characteristic | Group | ||
|---|---|---|---|
| Multidisciplinary Program | Personalized Care |
| |
|
|
| ||
| Gender, male | 40 (31) | 35 (27) | 0.583a |
| Age, years | 60 ± 11 | 59 ± 10 | 0.527b |
| Race | |||
| White | 98 (77) | 95 (74) | 0.652a |
| Yellow | 17 (13) | 22 (17) | |
| Black | 13 (10) | 11 (9) | |
| Years of education completed | |||
| 0 – 4 | 62 (48) | 59 (46) | 0.410a |
| 5 – 8 | 41 (32) | 50 (39) | |
| ≥ 9 | 25 (20) | 19 (15) | |
| Marital status | |||
| Married | 74 (58) | 78 (61) | 0.364a |
| Single | 14 (11) | 8 (6) | |
| Separated | 13 (10) | 19 (15) | |
| Widowed | 27 (21) | 23 (18) | |
| Social class, BARC | |||
| High, A/B | 37 (29) | 33 (26) | 0.277a |
| Medium, C | 62 (48) | 74 (58) | |
| Low, D/E | 29 (23) | 21 (16) | |
| BMI, Kg/m2 | 30 ± 0.5 | 30 ± 0.5 | 0.784b |
| Blood pressure, mmHg | |||
| Systolic | 156 ± 2 | 158 ± 2 | 0.437b |
| Diastolic | 89 ± 1 | 90 ± 1 | 0.633b |
| Comorbidity Index | |||
| CCI | 2 (1–3) | 2 (1–4) | 0.704c |
| CCI-Y | 4 (2–5) | 3 (2–5) | 0.951c |
| CIC-Y, survival 10 years | 53 (11–85) | 56 (16–82) | 0.843c |
| Comorbidity | |||
| Previous myocardial infarction | 16 (13) | 10 (8) | 0.214a |
| Heart failure | 22 (17) | 11 (9) | 0.040a |
| Peripheral vascular disease | 13 (10) | 13 (10) | 1.000a |
| Stroke | 18 (14) | 17 (13) | 0.856a |
| Diabetes Mellitus | 32 (23) | 34 (27) | 0.564a |
| COPD | 9 (7) | 5 (4) | 0.272a |
| Connective tissue disease | 57 (45) | 69 (54) | 0.134a |
| Gastric ulcers | 24 (19) | 24 (19) | 1.000a |
| Liver disease | 12 (9) | 13 (10) | 1.000a |
| Renal disease | 17 (13) | 20 (16) | 0.594a |
| Cancer | 10 (8) | 5 (4) | 0.237a |
| Smoking status | |||
| Never | 50 (43) | 52 (47) | 0.563a |
| Current | 25 (21) | 20 (18) | |
| Past | 42 (36) | 38 (35) | |
BARC Brazilian association of research companies, BMI Body mass index, CCI Charlson comorbidity index, CCI-Y Charlson comorbidity-year index, COPD Chronic obstructive pulmonary disease. Values expressed n (%), mean and standard error (SE) or median and interquartile range (IQR)
aPerson chi-square test or Fisher’s exact test
bStudent’s t-test
cMann-Whitney U test
Blood pressure and clinical measurements from baseline to end of study
| Variable | Group |
| |||
|---|---|---|---|---|---|
| Multidisciplinary Program | Personalized Care | Group | Time | Interaction | |
|
|
| ||||
| Systolic BP, mmHg | |||||
| Baseline | 156 ± 1.6 (128) | 158 ± 1.8 (128) | 0.575 | <0.001 | 0.600 |
| 6 Months | 144 ± 1.8 (114) | 143 ± 1.8 (113) | |||
| Δ | - 11.8 ± 20.2 | - 12.9 ± 19.2 | |||
| Diastolic BP, mmHg | |||||
| Baseline | 89 ± 1.02 (128) | 90 ± 1.03 (128) | 0.286 | <0.001 | 0.365 |
| 6 Months | 80 ± 1.03 (114) | 82 ± 1.09 (113) | |||
| Δ | - 8.10 ± 10.8 | - 7.0 ± 11.5 | |||
| BMI, Kg/m2 | |||||
| Baseline | 29.9 ± 0.5 (128) | 30.1 ± 0.5 (128) | 0.745 | 0.454 | 0.859 |
| 6 Months | 30 ± 0.5 (114) | 30.2 ± 0.5 (113) | |||
| Δ | 0.08 ± 1.9 | 0.13 ± 2.9 | |||
| WC, cm | |||||
| Baseline | 95.1 ± 1.7 (127) | 96.1 ± 1.2 (126) | 0.438 | 0.122 | 0.608 |
| 6 Months | 95.6 ± 1 (113) | 96.9 ± 1.1 (113) | |||
| Δ | 0.40 ± 5.9 | 0.82 ± 6.6 | |||
| WHR | |||||
| Baseline | 0.91 ± 0 (127) | 0.92 ± 0 (126) | 0.482 | 0.098 | 0.482 |
| 6 Months | 0.90 ± 0 (113) | 0.91 ± 0 (113) | |||
| Δ | - 0.012 ± 0.06 | - 0.003 ± 0.88 | |||
| Appointments, number | |||||
| Baseline | 3.82 ± 0.4 | 2.95 ± 0.2 | 0.258 | <0.001 | 0.084 |
| 6 Months | 1.9 ± 0.2 | 2.02 ± 0.2 | |||
| Δ | - 1.94 ± 0.4 | - 0.93 ± 0.3 | |||
| Physical activity, min per week | |||||
| Baseline | 87 ± 12 | 96 ± 14 | 0.114 | <0.001 | 0.110 |
| 6 Months | 188 ± 17 | 245 ± 27 | |||
| Δ | 103 ± 15 | 151 ± 26 | |||
BP Blood pressure, BMI Body mass index, WC Waist circumference, WHR Waist-to-hip ratio. Values expressed n (%), mean and standard error (SE), GEE Generalized estimating equationan overview of five randomized controlled
Blood pressure control from baseline to end of study
| Variables | Group | |||||||
|---|---|---|---|---|---|---|---|---|
| Multidisciplinary Program | Personalized Care | Between group | ||||||
| Baseline | 6 Months |
| Baseline | 6 Months |
| Baseline | 6 Months | |
|
|
|
|
|
| ||||
| Systolic BP | ||||||||
| Nondiabetic | 7 (9) | 40 (49) | <0.001 | 5 (7) | 44 (57) | <0.001 | 0.451 | 0.744 |
| Diabetic | 0 (0) | 9 (27) | 0.003 | 0 (0) | 8 (22) | 0.014 | ||
| Diastolic BP | ||||||||
| Nondiabetic | 37 (47) | 68 (86) | <0.001 | 36 (47) | 62 (81) | <0.001 | 0.697 | 0.473 |
| Diabetic | 6 (18) | 17 (52) | 0.003 | 5 (14) | 19 (53) | <0.001 | ||
BP blood pressure. BP control defined as systolic BP <140 or diastolic BP 90 mmHg for nondiabetic patients and systolic BP level <130 mmHg or diastolic BP <80 mmHg for diabetic patients. Values expressed n (%). Person chi-square test
Pharmacologic treatment
| Variable | Multidisciplinary Program | Personalized Care | Between groups | |||||
|---|---|---|---|---|---|---|---|---|
| Baseline | 6 Months |
| Baseline | 6 Months |
| Baseline | 6 Months | |
|
|
|
|
|
| ||||
| Medication class | ||||||||
| Not prescription | 5 (4) | 9 (8) | 0.289 | 13 (12) | 10 (8) | 0.453 | 0.084 | 0.984 |
| Antihypertensives | 94 (83) | 98 (86) | 0.289 | 94 (83) | 99 (88) | 0.063 | 0.743 | 0.845 |
| Antidiabetic | 29 (26) | 30 (27) | 1.000 | 31 (28) | 34 (31) | 0.508 | 0.388 | 0.558 |
| Antidepressive agents | 27 (24) | 25 (22) | 0.880 | 34 (30) | 29 (26) | 0.533 | 0.322 | 0.536 |
| Other cardiovascular drugs | 36 (32) | 40 (35) | 0.481 | 45 (40) | 5 (40) | 1.000 | 0.090 | 0.095 |
| Pulmonary | 5 (5) | 6 (5) | 1.000 | 6 (6) | 7 (6) | 1.000 | 0.769 | 0.784 |
| Hypolipidemic agents | 36 (32) | 40 (35) | 0.503 | 39 (35) | 41 (37) | 0.774 | 0.687 | 0.890 |
| Antihypertensive drugs | ||||||||
| Diuretics | 49 (44) | 55 (49) | 0.286 | 49 (44) | 59 (53) | 0.052 | 1.000 | 0.592 |
| Beta blockers | 31 (27) | 38 (34) | 0.118 | 35 (32) | 39 (36) | 0.424 | 0.342 | 1.000 |
| ACE | 66 (58) | 66 (58) | 1.000 | 63 (57) | 63 (57) | 1.000 | 0.704 | 0.789 |
| ARBs | 10 (9) | 13 (12) | 0.508 | 17 (16) | 23 (21) | 0.70 | 0.079 | 0.150 |
| CCB | 19 (17) | 22 (20) | 0.453 | 15 (14) | 21 (19) | 0.146 | 0.486 | 0.867 |
ACE Angiotensin-converting enzyme inhibitor, ARBs Angiotensin II Receptor Blockers, CCB Calcium channel blockers. Values expressed n (%). Person chi-square test
Behavioral and medication adherence
| Variable | Group | |||||||
|---|---|---|---|---|---|---|---|---|
| Multidisciplinary Program | Personalized Care | Between groups | ||||||
| Baseline | 6 Months |
| Baseline | 6 Months |
| Baseline | 6 Months | |
|
|
|
|
|
| ||||
| IPAC | ||||||||
| Active | 25 (22) | 56 (49) | 0.001 | 24 (21) | 59 (52) | <0.001 | 0.930 | 0.750 |
| Insufficient active | 39 (34) | 40 (35) | 41 (36) | 40 (35) | ||||
| Inactive | 50 (44) | 18 (16) | 48 (43) | 14 (12) | ||||
| Considers health | ||||||||
| Very bad | 7 (6) | 7 (6) | 0.133 | 8 (7) | 2 (2) | 0.047 | 0.701 | 0.253 |
| Bad | 13 (11) | 13 (11) | 14 (12) | 8 (7) | ||||
| Regular | 55 (48) | 44 (39) | 46 (41) | 42 (37) | ||||
| Good | 38 (33) | 45 (40) | 42 (37) | 53 (47) | ||||
| Very Good | 1 (1) | 5 (4) | 3 (3) | 8 (7) | ||||
| BP self-monitoring | ||||||||
| Every day | 16 (14) | 28 (25) | <0.001 | 13 (12) | 21 (19) | <0.001 | 0.532 | 0.473 |
| Once week | 28 (25) | 29 (25) | 22 (20) | 38 (34) | ||||
| Once month | 19 (17) | 42 (37) | 20 (18) | 36 (32) | ||||
| Rarely | 49 (43) | 13 (11) | 57 (50) | 17 (15) | ||||
| Never | 2 (1.8) | 2 (2) | 1 (1) | 1 (1) | ||||
| BMQ | ||||||||
| High adherence | 35 (35) | 69 (68) | <0.001 | 21 (22) | 64 (67) | <0.001 | 0.093 | 0.996 |
| Low adherence | 66 (65) | 32 (32) | 75 (78) | 32 (33) | ||||
| TMG | ||||||||
| Adherence | 34 (34) | 49 (49) | 0.008 | 34 (35) | 53 (55) | <0.001 | 0.635 | 0.810 |
| Moderate Adherent | 55 (55) | 47 (47) | 44 (46) | 39 (41) | ||||
| Low adherence | 12 (12) | 5 (5) | 18 (19) | 4 (4) | ||||
| Improved self-esteem | 90 (79) | 102 (90) | <0.001 | |||||
IPAC International Physical Activity Questionnaire, BP blood pressure, BMQ Brief Medication Questionnaire, TMG Test Morisky-Green, AUDIT Alcohol Use Disorder Identification Test. Values are n (%). Person chi-square test
Cardiovascular risk factors at the end of the study
| Variable | Group | ||
|---|---|---|---|
| Multidisciplinary Program | Personalized Care |
| |
|
|
| ||
| FBG, mg/dL | |||
| Diabetic | 137 ± 52 (32) | 135 ± 36 (33) | 0.905a |
| Nondiabetic | 92 ± 16 (68) | 93 ± 15 (67) | 0.712a |
| HbA1c, % | 6.6 ± 2 (32) | 6.4 ± 1 (33) | 0.634a |
| Total cholesterol, mg/dL | 191 ± 47 (107) | 198 ± 47 (104) | 0.263a |
| HDL, mg/dL | 45 ± 12 (107) | 45 ± 12 (104) | 0.916a |
| LDL, mg/dL | 113 ± 41 (96) | 119 ± 41 (98) | 0.297a |
| Triglyceride, mg/dL | 143 (113 – 190) (107) | 143 (112 – 213) (104) | 0.769b |
| Nondiabetic, 10 years FRS, n% | |||
| Low | 47 (63) | 39 (55) | 0.528c |
| Medium | 19 (25) | 24 (34) | |
| High | 9 (12) | 8 (11) | |
| Mean FRS | 5 (2–14) | 6 (3–14) | 0.647b |
| Diabetic, UKPDS, risk 10 year, % | |||
| CHD | 12 (8 – 17) (32) | 11 (6 – 19) | 0.572b |
| Fatal CHD | 7 (4–10) (32) | 6 (3 – 13) | 0.682b |
| Stroke | 7 (5 – 12) (32) | 5.5 (3 – 12) | 0.993b |
| Fatal Stroke | 1 (1 – 2) (32) | 1 (1 – 2) | 0.992b |
FBG Fasting blood glucose, HbA1c Glycated hemoglobin, HDL High-density lipoprotein, LDL Low-density lipoprotein cholesterol, FRS Framingham risk score, CVD Cardiovascular disease. Values expressed n (%), mean and standard deviation (SD) or median and interquartile range (IQR)
aStudent’s t-test
bMann-Whitney U test
cPerson chi-square test